The main aim of this study was to examine changes in subjective quality of life (general s-QoL) in patients with first-episode psychosis from baseline to 2 years follow-up. A total of 201 of 252 patients had full quality of life assessment at both baseline and at 2 years. Repeated measure analyses of variance were done to evaluate the development over time, and multiple linear regression analyses to evaluate predictors of change. These patients with a first-episode psychosis showed a significant improvement in general s-QoL during the first 2 years of treatment. Improvements in general s-QoL were associated with increase in excitative symptoms and with improvements in depressive symptoms, global functioning, level of daily activities, level of social activities, and perceived general health.
*Department of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; †Department of Psychiatry, University of Oslo, Oslo, Norway; ‡Psychiatric Clinic, Stavanger University Hospital, Stavanger, Norway; §Early Psychosis Intervention Center and University of Copenhagen, Zealand Region Psychiatry Roskilde, Roskilde, Denmark; ¶Department of Clinical Medicine, Section of Psychiatry, University of Bergen, Bergen, Norway; ∥Asker and Bærum Hospital, Vestre Viken Hospital Trust, Rud, Norway; **Department of Psychology, University of Oslo, Oslo, Norway; ††Psychiatric Research Unit and University of Copenhagen, Zealand Region Psychiatry Roskilde, Roskilde, Denmark; ‡‡Department of Behavioural Sciences in Medicine, University of Oslo, Oslo, Norway; and §§Department of Psychiatry, Yale University, New Haven, CT.
Supported by the Norwegian National Research Council (133897/320 and 154642/320), the Norwegian Department of Health and Social Affairs, the National Council for Mental Health/Health and Rehabilitation (1997/41 and 2002/306), Rogaland County and Oslo County (to P.V., J.O.J., S.F., T.K.L. I.M., and S.O.). Also, funded by the Theodore and Vada Stanley Foundation, the Regional Health Research Foundation for Eastern Region, Denmark; Roskilde County, Helsefonden, Lundbeck Pharma, Eli Lilly, and Janssen-Cilag Pharmaceuticals, Denmark (to E.S. and U.H.). Also, supported by a National Alliance for Research on Schizophrenia and Depression (NARSAD) Distinguished Investigator Award and NIMH grant MH-01654 (to T.M.) and a NARSAD Young Investigator Award (to T.K.L.).
Send reprint requests to Ingrid Melle, MD, PhD, Psychosis Research Unit, Department of Mental Health and Addiction, Oslo University Hospital, Kirkevn 166, 0407 Oslo, Norway. E-mail: email@example.com.